All Medicines
Dr. Aditya Singh

Medically Reviewed By

Dr. Aditya Singh, MBBS, MD (Pharmacology)

Reg No: MCI-654321 • Verified Medical Reviewer

Immunosuppressants

Sotyktu

(deucravacitinib)

Uses, side effects, dosage information & price range

Bristol-Myers Squibb Pharma EEIG

About this medicine

Plaque psoriasis Sotyktu is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Psoriatic arthritis Sotyktu, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adults who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic (DMARD) therapy.

Common Substitutes & Alternatives

These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.

Pomalidomide ZentivaComposition: pomalidomideZentiva, k.s.
Price on RequestView Details →
UpliznaComposition: inebilizumabAmgen Europe B.V.
Price on RequestView Details →
VeblocemaComposition: infliximabCelltrion Healthcare Hungary Kft.
Price on RequestView Details →
AravaComposition: leflunomideSanofi-aventis Deutschland GmbH
Price on RequestView Details →
CimziaComposition: certolizumab pegolUCB Pharma
Price on RequestView Details →

Key Information

Salt / Composition

deucravacitinib

Category

Immunosuppressants

Manufacturer

Bristol-Myers Squibb Pharma EEIG

Need a doctor's consultation?

Don't self-medicate. Consult a doctor before taking any medicine.

Medical Disclaimer

This information is for educational purposes only and is not a substitute for professional medical advice. Always consult your doctor or pharmacist before taking any medication. Prices are indicative and may vary. Do not start, stop, or change the dosage of any medicine without your doctor's approval.

Disclaimer:Content on this page is for informational purposes only. Do not consume prescription medication without a registered practitioner's direct oversight.